Company insider dossier

Vericel Corp Ord insider intelligence

VCEL filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
62/100

Accumulation bias

92/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
3 Aug 2026

Investment committee read

Accumulation bias

Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.

Watch for market confirmation

Evidence in favour

  • 12 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 11 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 03 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction62Accumulation bias
Confidence92Deep evidence
Named insiders11participating in the tape
Controlled events31directional common-share events
Acquisition value$1.3Mnormalized amount
Disposal value$4.1Mnormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

57.0950.1543.2236.2829.34 Disposal · 3 Aug 2026 · $468.4KAcquisition · 3 Aug 2026 · $166.6KDisposal · 30 Jul 2026 · $122.2KAcquisition · 30 Jul 2026 · $74.5KDisposal · 30 Jul 2026 · $73.3KAcquisition · 30 Jul 2026 · $52.4KDisposal · 30 Jul 2026 · $24.4KAcquisition · 30 Jul 2026 · $14.9KDisposal · 26 Jun 2026 · $684.6KAcquisition · 26 Jun 2026 · $243.8KDisposal · 26 Jun 2026 · $225.0KDisposal · 26 Jun 2026 · $223.8KAcquisition · 26 Jun 2026 · $149.1KDisposal · 26 Jun 2026 · $112.2KAcquisition · 26 Jun 2026 · $74.5KDisposal · 26 Jun 2026 · $10.4KDisposal · 18 Jun 2026 · $603.1KDisposal · 18 Jun 2026 · $402.4KAcquisition · 18 Jun 2026 · $243.8KAcquisition · 18 Jun 2026 · $166.6KDisposal · 2 Jun 2026 · $153.1KAcquisition · 2 Jun 2026 · $72.9KDisposal · 13 May 2026 · $114.9KDisposal · 13 May 2026 · $114.9KAcquisition · 13 May 2026 · $45.7KAcquisition · 13 May 2026 · $9.2KDisposal · 11 May 2026 · $244.8KDisposal · 11 May 2026 · $82.6KDisposal · 7 May 2026 · $202.5KDisposal · 7 May 2026 · $57.6KDisposal · 6 May 2026 · $130.5KAcquisition · 29 Apr 2026 · Not reportedAcquisition · 29 Apr 2026 · Not reportedAcquisition · 29 Apr 2026 · Not reportedAcquisition · 29 Apr 2026 · Not reportedAcquisition · 29 Apr 2026 · Not reportedAcquisition · 29 Apr 2026 · Not reported
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
45.09 USD
One-week move
-1.9%
Four-week move
-4.1%
Fair-value gap
+7.7%
Trend signal
Active
Relative strength
7.2

Directional balance

Controlled event mix

38.7%acquisition
Acquisition events
12
Disposal events
19
Net value
-$2.7M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
301 Jun
008 Jun
615 Jun
1122 Jun
029 Jun
006 Jul
013 Jul
020 Jul
927 Jul
303 Aug
010 Aug

Named participants

Insider conviction by person

SIEGAL, JONATHANPrincipal Accounting Officer6311 events
HOPPER, JONATHAN MARKChief Medical Officer634 events
HALPIN, MICHAELChief Operating Officer624 events
FLYNN, SEAN C.Chief Legal Officer624 events
MCLAUGHLIN, KEVIN FDirector624 events
HAGEN, HEIDIDirector500 events
RUBINO, ALAN LDirector500 events
WRIGHT, LISADirector500 events
ZERBE, ROBERT L MDDirector500 events
MARA, JOSEPH ANTHONY JRChief Financial Officer252 events
WOTTON, PAUL KDirector252 events

Evidence quality

Security and transaction context

Common equity37
Equity compensation8
Options and derivatives17
Other securities0

Role architecture

Who is participating

Other executive33
Director27
Finance leadership2

Transaction evidence

Auditable VCEL filing ledger

Showing 31 to 60 of 62.

HOPPER, JONATHAN MARKChief Medical Officer
DisposalCommon equity
4375 sharesCommon Stock
$153.1KDirectional evidence
HOPPER, JONATHAN MARKChief Medical Officer
AcquisitionCommon equity
4375 sharesCommon Stock
$72.9KDirectional evidence
MCLAUGHLIN, KEVIN FDirector
AcquisitionOptions and derivatives
3500 sharesStock Option (Right to Buy)
Not reportedContext evidence
MCLAUGHLIN, KEVIN FDirector
DisposalCommon equity
3500 sharesCommon Stock
$114.9KDirectional evidence
MCLAUGHLIN, KEVIN FDirector
DisposalCommon equity
3500 sharesCommon Stock
$114.9KDirectional evidence
MCLAUGHLIN, KEVIN FDirector
AcquisitionCommon equity
3500 sharesCommon Stock
$45.7KDirectional evidence
MCLAUGHLIN, KEVIN FDirector
AcquisitionCommon equity
3500 sharesCommon Stock
$9.2KDirectional evidence
WOTTON, PAUL KDirector
DisposalCommon equity
7500 sharesCommon Stock
$244.8KDirectional evidence
WOTTON, PAUL KDirector
DisposalCommon equity
2500 sharesCommon Stock
$82.6KDirectional evidence
MARA, JOSEPH ANTHONY JRChief Financial Officer
DisposalCommon equity
5000 sharesCommon Stock
$202.5KDirectional evidence
SIEGAL, JONATHANPrincipal Accounting Officer
DisposalCommon equity
1422 sharesCommon Stock
$57.6KDirectional evidence
SIEGAL, JONATHANPrincipal Accounting Officer
DisposalCommon equity
3433 sharesCommon Stock
$130.5KDirectional evidence
HAGEN, HEIDIDirector
AcquisitionOptions and derivatives
8000 sharesStock Option (Right to Buy)
Not reportedContext evidence
HAGEN, HEIDIDirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence
HAGEN, HEIDIDirector
AcquisitionCommon equity
3200 sharesCommon Stock
Not reportedContext evidence
MCLAUGHLIN, KEVIN FDirector
AcquisitionOptions and derivatives
8000 sharesStock Option (Right to Buy)
Not reportedContext evidence
MCLAUGHLIN, KEVIN FDirector
AcquisitionCommon equity
3200 sharesCommon Stock
Not reportedContext evidence
MCLAUGHLIN, KEVIN FDirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence
RUBINO, ALAN LDirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence
RUBINO, ALAN LDirector
AcquisitionCommon equity
3200 sharesCommon Stock
Not reportedContext evidence
RUBINO, ALAN LDirector
AcquisitionOptions and derivatives
8000 sharesStock Option (Right to Buy)
Not reportedContext evidence
WOTTON, PAUL KDirector
AcquisitionCommon equity
3200 sharesCommon Stock
Not reportedContext evidence
WOTTON, PAUL KDirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence
WOTTON, PAUL KDirector
AcquisitionOptions and derivatives
8000 sharesStock Option (Right to Buy)
Not reportedContext evidence
WOTTON, PAUL KDirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence
WRIGHT, LISADirector
AcquisitionOptions and derivatives
8000 sharesStock Option (Right to Buy)
Not reportedContext evidence
WRIGHT, LISADirector
AcquisitionCommon equity
3200 sharesCommon Stock
Not reportedContext evidence
WRIGHT, LISADirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence
WRIGHT, LISADirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence
ZERBE, ROBERT L MDDirector
AcquisitionEquity compensation
3200 sharesRestricted Stock Unit
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context